You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

370 Results
Regimen
Cancer Type:
Gynecologic, 
Endometrial
Intent: Adjuvant, Curative, Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - Primary Advanced or Recurrent Endometrial Carcinoma
Sep 2025
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Intent: Palliative
Funding:
New Drug Funding Program
    Nivolumab plus Ipilimumab – Previously Untreated Unresectable or Advanced Hepatocellular Carcinoma
New Drug Funding Program
    Nivolumab plus Ipilimumab – Previously Untreated Unresectable or Advanced Hepatocellular Carcinoma
Jan 2026
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Intent: Palliative
Funding:
New Drug Funding Program
    Nivolumab plus Ipilimumab – Previously Untreated Unresectable or Advanced Hepatocellular Carcinoma
Jan 2026
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Neoadjuvant, Curative
Sep 2025
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Adjuvant, Curative
Sep 2025
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Neoadjuvant, Curative
Sep 2025
Guidelines and Advice
Status: Current
ID: GL1-10
Version: 4
Mar 2024
Drug
Other Name(s): Poteligeo®
May 2024
Drug
Other Name(s): Avastin® , Mvasi®; Zirabev®; Bambevi®; Abevmy®; Aybintio®; Vegzelma™
Nov 2024
Drug
Other Name(s): Velcade®
Nov 2024

Pages